Evidence map›Paper›PMID 26080734›Full record

ArticleNature communications2015

Artificial membrane-binding proteins stimulate oxygenation of stem cells during engineering of large cartilage tissue.

James P K Armstrong, Rameen Shakur, Joseph P Horne, Sally C Dickinson, Craig T Armstrong, Katherine Lau, Juned Kadiwala, Robert Lowe, Annela Seddon, Stephen Mann and 3 more

Open access · goldAbstract readEvaluation Study
In one paragraph

Article in Nature communications, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Cell-drug conjugates.Nature biomedical engineering · 2024
    Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Cell augmentation strategies for cardiac stem cell therapies.Stem cells translational medicine · 2021
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

James P K ArmstrongBristol Centre for Functional Nanomaterials, University of Bristol, Bristol BS8 1FD, UK.
Rameen ShakurWellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Cambridge CB10 1SA, UK.
Joseph P HorneSchool of Cellular and Molecular Medicine, University of Bristol, Bristol BS8 1TD, UK.
Sally C DickinsonSchool of Cellular and Molecular Medicine, University of Bristol, Bristol BS8 1TD, UK.
Craig T ArmstrongSchool of Biochemistry, University of Bristol, Bristol BS8 1TD, UK.
Katherine LauRenishaw plc, Spectroscopy Products Division, Wotton-Under-Edge GL12 7DW, UK.
Juned KadiwalaWellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Cambridge CB10 1SA, UK.
Robert LoweThe Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, UK.
Annela SeddonBristol Centre for Functional Nanomaterials, University of Bristol, Bristol BS8 1FD, UK.
Stephen MannCentre for Organized Matter Chemistry and Centre for Protolife Research, School of Chemistry, University of Bristol, Bristol BS8 1TS, UK.
J L Ross AndersonSchool of Biochemistry, University of Bristol, Bristol BS8 1TD, UK.
Adam W PerrimanCentre for Organized Matter Chemistry and Centre for Protolife Research, School of Chemistry, University of Bristol, Bristol BS8 1TS, UK.
Anthony P HollanderSchool of Cellular and Molecular Medicine, University of Bristol, Bristol BS8 1TD, UK.
University of Bristol · GBWellcome Sanger Institute · GBQueen Mary University of London · GBRenishaw (United Kingdom) · GB

Funding

Medical Research Council MR/K015648Medical Research Council MR/K015648/1Medical Research Council MR/K015648/2
6 · The paper itself

Abstract

Restricted oxygen diffusion can result in central cell necrosis in engineered tissue, a problem that is exacerbated when engineering large tissue constructs for clinical application. Here we show that pre-treating human mesenchymal stem cells (hMSCs) with synthetic membrane-active myoglobin-polymer-surfactant complexes can provide a reservoir of oxygen capable of alleviating necrosis at the centre of hyaline cartilage. This is achieved through the development of a new cell functionalization methodology based on polymer-surfactant conjugation, which allows the delivery of functional proteins to the hMSC membrane. This new approach circumvents the need for cell surface engineering using protein chimerization or genetic transfection, and we demonstrate that the surface-modified hMSCs retain their ability to proliferate and to undergo multilineage differentiation. The functionalization technology is facile, versatile and non-disruptive, and in addition to tissue oxygenation, it should have far-reaching application in a host of tissue engineering and cell-based therapies.

Indexed as

Hyaline CartilageEscherichia coliGlycolatesHumansMesenchymal Stem CellsMyoglobinOxygenTissue EngineeringGlycolatesglycolic acid ethoxylate 4-nonylphenyl etherMyoglobinOxygen

Identifiers

PMID26080734
PMCPMC4557285
OpenAlexW1929377110

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.